Charlie’s Holdings (OTCQB:CHUC) Selected for FDA Premarket Tobacco Product Applications Meeting

Charlie’s Director, Dr. Ed Carmines, an expert on regulatory submissions and product safety, will discuss Pharmacological Profiles at the prestigious FDA roundtable.

COSTA MESA, CA / ACCESS Newswire / February 10, 2026 / Charlie’s Holdings, Inc. (OTCQB:CHUC) (“Charlie’s” or the “Company“), an industry leader in the premium vapor products space, today reported that the Center for Tobacco Products of the U.S. Food and Drug Administration (“FDA”) selected Charlie’s Board member, Ed Carmines, PhD, to serve as a panelist for the Roundtable on Premarket Tobacco Product Application (“PMTA”) Submissions for Electronic Nicotine Delivery Systems (“ENDS”) that will be held at 9:00am (Eastern Time) today at FDA Headquarters in Silver Spring, Maryland.

Dr. Ed Carmines, Chief Scientific Officer of Chemular, Inc, and independent Board Member of Charlie’s Holdings, is a world-renowned expert in the technical aspects of all types of e-cigarettes, oral tobacco, tobacco-free products, cigars, and cigarettes. Having successfully navigated the FDA’s Substantial Equivalence, PMTA, and Modified Risk Tobacco Product Application (“MRTPA”) pathways for literally thousands of products, Dr. Carmines spearheaded development and licensing of proprietary technology to enable Charlie’s to offer a controlled e-cigarette device that is made operable only upon activation by an age-verified adult consumer.

By launching this strategic initiative, Charlie’s has endeavored to make the Company’s PACHA™ disposable e-cigarette products the first flavored e-cigarettes able to be sold legally in the United States.

During today’s FDA roundtable, Dr. Carmines will discuss pharmacokinetic studies around Charlie’s PACHA products as well as studies of adult benefits related to flavored ENDS products that could result in Charlie’s becoming the first Company to demonstrate to the FDA that age-gated flavored vape products are indeed ‘appropriate for the protection of public health.’

The FDA roundtable discussion will be available for viewing online.

For more information about providing comments, orally or in writing, please see the Federal Register notice.

About Charlie’s Holdings, Inc.

Charlie’s Holdings, Inc. (OTCQB:CHUC) is an industry leader in the premium vapor products space. The Company’s products are sold around the world to select distributors, specialty retailers, and third-party online resellers through subsidiary company Charlie’s Chalk Dust, LLC has developed an extensive portfolio of brand styles, flavor profiles, and innovative product formats.

For additional information, please visit Charlie’s corporate website at: Chuc.comand the Company’s branded online websites: sbxvape.com, CharliesChalkDust.com, enjoypachamama.com, and Pacha.co.

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company’s overall business, existing and anticipated markets and expectations regarding future sales and expenses. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms, and similar expressions, are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ongoing ability to quote its shares on the OTCQB; whether the Company will meet the requirements to up-list to a national securities exchange in the future; the Company’s ability to successfully increase sales and enter new markets; whether the Company’s PMTA’s for its nicotine-containing products will be authorized by the FDA, and the FDA’s decisions with respect to the Company’s future PMTA’s for nicotine products; the Company’s ability to manufacture and produce products for its customers; the Company’s ability to formulate new products; the acceptance of existing and future products; the complexity, expense and time associated with compliance with government rules and regulations affecting nicotine, synthetic nicotine, products containing nicotine substitutes, and products containing cannabidiol; litigation risks from the use of the Company’s products; risks of government regulations; the impact of competitive products; and the Company’s ability to maintain and enhance its brands, as well as other risk factors included in the Company’s most recent quarterly report on Form 10-Q, annual report on Form 10-K, and other SEC filings. These forward-looking statements are made as of the date of this press release and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.

Investors Contact:

IR@charliesholdings.com
Phone: 949-570-0691

SOURCE: Charlie’s Holdings, Inc.

View the original press release on ACCESS Newswire